

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**WUXI APPTEC CO., LTD.\***  
**無錫藥明康德新藥開發股份有限公司**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*  
**(Stock Code: 2359)**

**2019 THIRD QUARTERLY REPORT**

This announcement is made pursuant to Rule 13.09(2) and Rule 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong).

The following is the third quarterly report for 2019 of WuXi AppTec Co., Ltd.\* (無錫藥明康德新藥開發股份有限公司) (the “**Company**”, together with its subsidiaries, collectively the “**Group**”) (the “**2019 Third Quarterly Report**”). The financial report therein is prepared in accordance with the PRC Accounting Standards for Business Enterprises or the International Financial Reporting Standards (the “**IFRSs**”) issued by the International Accounting Standards Board and has not been audited.

By Order of the Board  
**WuXi AppTec Co., Ltd.\***  
**Dr. Ge Li**  
*Chairman*

Hong Kong, October 30, 2019

*As of the date of this announcement, the Board of the Company comprises Dr. Ge Li, Mr. Edward Hu, Mr. Xiaozhong Liu, Mr. Zhaohui Zhang and Dr. Ning Zhao as executive Directors, Mr. Xiaomeng Tong and Dr. Yibing Wu as non-executive Directors and Dr. Jiangnan Cai, Ms. Yan Liu, Mr. Dai Feng, Dr. Hetong Lou and Mr. Xiaotong Zhang as independent non-executive Directors.*

\* *For identification purpose only*

## I. Important Notice

- 1.1 The board of directors (the “**Board**” or “**Board of Directors**”), the Supervisory Committee and the directors, supervisors and senior management of the Company warrant the truthfulness, accuracy and completeness of the contents of the 2019 Third Quarterly Report and that there are no false information, misleading statements or material omissions in the 2019 Third Quarterly Report, and shall assume joint and several legal responsibilities.
- 1.2 All Directors attended the Board meeting to review the 2019 Third Quarterly Report.
- 1.3 Ge Li, the person in charge of the Company, Ellis Bih-Hsin Chu, the Chief Financial Officer and Jin Sun, the Director of the Accounting Department warrant the truthfulness, accuracy and completeness of the financial statements contained in the 2019 Third Quarterly Report.
- 1.4 The 2019 Third Quarterly Report of the Company has not been audited.
- 1.5 Definitions

### Definitions of frequently-used terms

“2018 Profit Distribution Plan”	the profit distribution plan of the Company for the year ended December 31, 2018 including the Capitalization of Reserve and the distribution of cash dividend of RMB5.80 for every 10 Shares (inclusive of tax)
“2018 WuXi AppTec A Share Incentive Scheme” or “Restricted A Shares and Stock Option Incentive Plan of 2018”	the share incentive scheme adopted by the Company on August 22, 2018
“2019 A Share Incentive Plan”	Restricted A Share and Stock Option Incentive Plan of 2019 of the Company
“2019 Share Appreciation Scheme”	Share Appreciation Incentive Scheme of 2019 of the Company
“2019 Share Incentive Schemes”	the 2019 A Share Incentive Plan and the 2019 Share Appreciation Scheme of the Company

“A Share(s)”	domestic shares of the Company, with a nominal value of RMB1.00 each, which are listed for trading on the Shanghai Stock Exchange and traded in RMB
“Capitalization of Reserve”	the issue of 4 Capitalization Shares for every 10 Shares by way of capitalization of reserve
“Capitalization Shares”	the new Shares allotted and issued under the Capitalization of Reserve by the Company
“China” or “PRC”	the People’s Republic of China, which for the purpose of this quarterly report and for geographical reference only, excludes Hong Kong, Macau and Taiwan
“Company”, “the Company” or “WuXi AppTec”	WuXi AppTec Co., Ltd. (無錫藥明康德新藥開發股份有限公司)
“Director(s)”	the director(s) of the Company
“end of the Reporting Period”	September 30, 2019
“H Share(s)”	overseas listed foreign shares in the share capital of the Company with nominal value of RMB1.00 each, which are listed on the Stock Exchange
“Incentive Participants”	the persons to be granted Restricted A Share(s), Share Option(s) or Share Appreciation Right(s) under the 2019 Share Incentive Schemes, including the Directors, senior management, mid-level management, backbone members of technicians, basic-level management and other technicians of the Company
“Reporting Period”	the period from January 1, 2019 to September 30, 2019
“Restricted A Shares”	the restricted A Shares granted by the Company under the 2018 WuXi AppTec A Share Incentive Scheme
“RMB” or “RMB million”	Renminbi yuan or million yuan

“Share(s)”	ordinary shares in the capital of the Company with a nominal value of RMB1.00 each, comprising A Shares and H Shares
“Shareholder(s)”	holder(s) of Shares
“Share Appreciation Rights”	rights granted to the Incentive Participants under the 2019 Share Appreciation Scheme
“Share Options”	share options granted under the 2019 A Share Incentive Plan
“STA”	Shanghai SynTheAll Pharmaceutical Co., Ltd. (上海合全藥業股份有限公司)
“Stock Exchange”	The Stock Exchange of Hong Kong Limited
“Supervisory Committee”	the supervisory committee of the Company
“U.S.”	the United States of America, its territories, its possession and all areas subject to its jurisdiction
“WXAT Shanghai”	WuXi AppTec (Shanghai) Co., Ltd. (上海藥明康德新藥開發有限公司)

## II. Company Profile

The Company is a leading global pharmaceutical research and development services platform. Headquartered in Shanghai, China, the Company provides comprehensive and integrated platform services of discovery, development and manufacturing of small molecule drugs for over 3,700 customers through 29 operation sites and branch offices across the globe, including in China, U.S. and Europe. It provides global pharmaceutical companies with discovery, manufacturing and supporting services of new drugs through a platform covering the entire industry chain, and also offers certain testing services for medical devices as well as research, development and manufacturing services of precision medicine. As at the end of the Reporting Period, the Company had 21,463 employees, including 7,395 employees with a master's or higher degree and 1,002 employees with a Ph.D. or equivalent degree. A breakdown of our employees by function and by geography is set out below:

<b>Position</b>	<b>China (including Hong Kong)</b>	<b>U.S.</b>	<b>Europe</b>	<b>Total</b>
Research and development	16,764	826	44	17,634
Manufacturing	1,415	234	—	1,649
Sales	22	70	9	101
Management and administration	1,653	418	8	2,079
Total	<u>19,854</u>	<u>1,548</u>	<u>61</u>	<u>21,463</u>

To maintain the high service standards, industry leading expertise and continuously meet customers' demands, the Company will continue to recruit, train, promote and retain talented individuals.

## 2.1 Major financial data

	Unit: RMB		
	As at the end of the Reporting Period	As at the end of the previous year	Increase/ decrease (%)
Total assets	27,370,406,690.32	22,667,201,900.81	20.75
Net assets attributable to shareholders of the Company	17,219,160,719.52	17,688,020,821.28	-2.65
	From the beginning of the year to the end of the Reporting Period (January to September)	From the beginning of the previous year to the end of last reporting period (January to September)	Increase/ decrease (%)
Net cash flow from operating activities	1,773,185,018.60	917,299,030.50	93.31
	From the beginning of the year to the end of the Reporting Period (January to September)	From the beginning of the previous year to the end of last reporting period (January to September)	Increase/ decrease (%)
Revenue	9,278,514,251.38	6,921,135,001.68	34.06
Net profit attributable to shareholders of the Company	1,765,146,773.87	1,928,376,253.99	-8.46
Net profit attributable to shareholders of the Company after deducting non-recurring gain or loss items	1,714,238,075.88	1,252,360,771.76	36.88
Weighted average return on equity (%)	9.89	22.62	Decreased by 12.73 percentage points
Basic earnings per share (RMB/share)	1.08	1.39	-22.30
Diluted earnings per share (RMB/share)	1.07	1.38	-22.46

Net profit attributable to shareholders of the Company for the Reporting Period recorded a decrease of 8.46%, which was mainly due to a significant decrease of RMB714.22 million in the fair value change of invested portfolio companies, from a gain of RMB668.82 million for the corresponding period of the previous year to a loss of RMB45.40 million. Without taking into account the fair value change of invested portfolio companies, the net profit attributable to shareholders of the Company for the Reporting Period recorded an increase of 43.74% as compared with the corresponding period of the previous year.

The weighted average return on equity for the Reporting Period decreased by 12.73 percentage points mainly due to the increase in net assets as the Company listed its H Shares on the Stock Exchange in December 2018.

In July 2019, pursuant to the 2018 Profit Distribution Plan considered and approved by the shareholders' general meeting, the Company issued 4 Shares for every 10 Shares of the Company by way of capitalization of reserve and 468,012,375 Shares were issued in aggregate. The total share capital of the Company changed from 1,170,030,939 Shares to 1,638,043,314 Shares. In accordance with the regulations of the China Securities Regulatory Commission, the Company has adjusted the basic earnings per share and diluted earnings per share for the comparative period according to the 2018 Profit Distribution Plan.

## *Non-recurring gain or loss items and amounts*

✓ Applicable    □ Not applicable

Unit: RMB

Item	Amount for the period (July to September)	Amount for the period from the beginning of the year to the end of the Reporting Period (January to September)	Description
Gain or loss on disposal of non-current assets	-1,340,989.38	-3,377,144.47	
Government grants included in profit or loss of the current period (except for those closely related to the Company's normal operation and which were granted on a recurring basis subject to certain amount or volume upon fulfilment of specific standards in compliance with the government policies and regulations)	34,970,110.35	103,938,040.45	
Gain or loss arising from changes in fair value of holding held-for-trading financial assets, derivative financial assets, held-for-trading financial liabilities and derivative financial liabilities, and investment income from disposal of held-for-trading financial assets, derivative financial assets, held-for-trading financial liabilities, derivative financial liabilities and other equity investments, except effective hedging business related to the Company's normal operations	-56,288,992.11	-37,519,943.25	Include: A loss of RMB115.26 million from fair value changes in foreign currency forward contracts for the holding period and settlement and a loss of RMB45.40 million from fair value changes in investment portfolios, offset by a gain of RMB49.83 million from disposal of investment portfolios and a gain of RMB73.31 million on held-for-trading financial assets for the holding period and disposal
Other non-operating income and expenses other than the above items	472,093.50	-1,389,139.09	
Impact on minority interests (after tax)	1,829,623.94	-873,246.19	
Effect of income tax	7,474,807.62	-9,869,869.46	
<b>Total</b>	<b>-12,883,346.08</b>	<b>50,908,697.99</b>	



## 2.2 Total number of Shareholders and shareholdings of top 10 Shareholders and top 10 holders of tradable Shares (or Shareholders holding Shares not subject to trading restrictions) as at the end of the Reporting Period

							Unit: share
Total number of Shareholders							38,622
Shareholdings of top 10 Shareholders							
Full name of Shareholder	Number of Shares held as at the end of the Reporting Period	Percentage (%)	Number of Shares subject to Trading restrictions	Pledged or frozen Shares		Nature of Shareholder	
				Status	Number		
HKSCC NOMINEES LIMITED ( <i>Note 1</i> )	170,490,867	10.4104	0	Unknown	0	Overseas legal entity	
WuXi AppTec (BVI) Inc.	113,400,000	6.9243	0	Nil	0	Overseas legal entity	
G&C VI Limited	113,400,000	6.9243	113,400,000	Nil	0	Overseas legal entity	
SUMMER BLOOM INVESTMENTS (I) PTE. LTD.	103,660,271	6.3296	0	Nil	0	Overseas legal entity	
Glorious Moonlight Limited	94,744,758	5.7852	0	Nil	0	Overseas legal entity	
G&C IV Hong Kong Limited	82,928,160	5.0637	82,928,160	Nil	0	Overseas legal entity	
CDB Boyu (Shanghai) Investment Management Company Limited — Jiashi Kangheng (Tianjian) Investments Partnership (Limited Partnership)	80,885,497	4.9390	0	Nil	0	Domestic non-state owned legal entity	
HCFII WX (HK) Holdings Limited	63,550,258	3.8804	0	Nil	0	Overseas legal entity	
G&C V Limited	57,946,140	3.5383	57,946,140	Nil	0	Overseas legal entity	
Shanghai Zhongmin Yinfu Investment Management Co., Ltd. — Jiaxing Yuxiang Investment Partnership (Limited Partnership)	51,830,100	3.1648	51,830,100	Nil	0	Domestic non-state owned legal entity	

**Shareholdings of top 10 holders of Shares not subject to trading restrictions**

Name of Shareholder	Number of Shares not subject to trading restrictions	Class and number of Shares	
		Class	Number
HKSCC NOMINEES LIMITED <i>(Note 1)</i>	170,490,867	Overseas-listed foreign shares	170,490,867
WuXi AppTec (BVI) Inc.	113,400,000	RMB-denominated ordinary shares	113,400,000
SUMMER BLOOM INVESTMENTS (I) PTE. LTD.	103,660,271	RMB-denominated ordinary shares	103,660,271
Glorious Moonlight Limited	94,744,758	RMB-denominated ordinary shares	94,744,758
CDB Boyu (Shanghai) Investment Management Company Limited — Jiashi Kangheng (Tianjian) Investments Partnership (Limited Partnership)	80,885,497	RMB-denominated ordinary shares	80,885,497
HCFII WX (HK) Holdings Limited	63,550,258	RMB-denominated ordinary shares	63,550,258
ABG-WX HOLDING (HK) LIMITED	49,014,520	RMB-denominated ordinary shares	49,014,520
Hong Kong Securities Clearing Company Limited <i>(Note 2)</i>	45,369,032	RMB-denominated ordinary shares	45,369,032
Shanghai Jingyao Investment Management Co., Ltd.	33,912,606	RMB-denominated ordinary shares	33,912,606
The Hongkong and Shanghai Banking Corporation Limited	30,753,020	RMB-denominated ordinary shares	30,753,020
Description of connected relationships or concerted actions of the above Shareholders	G&C VI Limited, G&C IV Hong Kong Limited and G&C V Limited, being part of the top 10 Shareholders of the Company, are under control of Ge Li. Close family member(s) of Xiaomeng Tong (a director of the Company who was nominated by Glorious Moonlight Limited) holds shares of Boyu (Shanghai) Investment Management Company Limited, the ultimate controller of Jiashi Kangheng (Tianjian) Investments Partnership (Limited Partnership). The Company is not aware of any connected relationship among the top 10 Shareholders not subject to trading restrictions, or whether they are parties acting in concert as defined under the Measures for the Administration of the Takeover of Listed Companies (《上市公司收 購管理辦法》).		
Description of preference shareholders with voting rights restored and their shareholdings	N/A		

*Note 1:* HKSCC NOMINEES LIMITED holds shares on behalf of its multiple clients.

*Note 2:* Hong Kong Securities Clearing Company Limited is the nominee holder of the RMB denominated ordinary shares under the Shanghai-Hong Kong Stock Connect.

### 2.3 Total number of preference Shareholders and shareholdings of top 10 preference Shareholders and top 10 preference Shareholders not subject to trading restrictions as at the end of the Reporting Period

Applicable  Not applicable

### III. Significant Events

#### 3.1 Significant changes in major financial statement items and financial indicators of the Company and the reasons thereof

Applicable  Not applicable

Unit: RMB

Item of Consolidated Income Statement	From the beginning of the year to the end of the Reporting Period (January — September)	From the beginning of last year to the end of the reporting period of last year (January — September)	Change (%)	Reasons
Revenue	9,278,514,251.38	6,921,135,001.68	34.06	During the Reporting Period, there was a rapid growth of each business segment.
Cost	5,612,735,942.99	4,105,515,828.51	36.71	During the Reporting Period, cost increase aligned with the revenue trend. The Company continued to strengthen its production capacities and capabilities, and expanded incentives for its key personnel, resulting in a higher increase in cost compared to revenue.
Selling and marketing expenses	313,174,962.20	233,016,820.00	34.40	Higher staff costs due to further growth in business scale during the Reporting Period.

<b>Item of Consolidated Income Statement</b>	<b>From the beginning of the year to the end of the Reporting Period (January — September)</b>	<b>From the beginning of last year to the end of the reporting period of last year (January — September)</b>	<b>Change (%)</b>	<b>Reasons</b>
Administrative expenses	1,028,463,979.83	767,659,847.16	33.97	Staff costs, including the expense incurred for 2018 WuXi AppTec A Share Incentive Scheme, service fee and depreciation and amortization expense increased during the Reporting Period.
Research and development expenses	414,319,379.97	297,004,655.82	39.50	Staff costs and material costs of research and development projects increased during the Reporting Period.
Finance expenses	-100,488,321.63	3,350,960.72	-3,098.79	During the Reporting Period, there was an increase in interest income from the unutilized proceeds deposited at banks, a decrease in interest expenses due to lower average borrowings and an increase in foreign exchange gains due to fluctuation of exchange rate.
Other income	103,553,177.55	51,278,911.07	101.94	Government subsidies relating to ordinary business and assets increased during the Reporting Period.
Investment gains	199,593,997.90	36,451,586.77	447.56	During the Reporting Period, gains from equity interest in our investee, WuXi Healthcare Ventures II L.P., increased, and gains from transfer of shares of certain listed investees were recorded.

<b>Item of Consolidated Income Statement</b>	<b>From the beginning of the year to the end of the Reporting Period (January — September)</b>	<b>From the beginning of last year to the end of the reporting period of last year (January — September)</b>	<b>Change (%)</b>	<b>Reasons</b>
Gains from changes in fair value	-132,176,799.62	590,231,365.46	-122.39	Due to changes in fair value of investment in listed companies namely Unity Biotechnology, Inc. and Hua Medicine.
Credit impairment losses	-10,038,827.73	-157,534.33	N/A	Trade receivables and contract assets increased at the end of the Reporting Period, which caused the credit impairment losses under expected credit loss model increased correspondingly.
Gains on assets disposal	1,035,391.87	-310,528.26	N/A	Gains on the disposal of unused instruments increased during the Reporting Period.
Non-operating income	1,342,760.21	14,591,580.22	-90.80	Government subsidies relating to non-operating business decreased during the Reporting Period.
Non-operating expenses	6,759,572.67	4,727,298.25	42.99	Retirement or disposal of assets increased during the Reporting Period.
Income tax expenses	327,543,076.13	199,561,718.38	64.13	Profit before tax increased during the Reporting Period.

Unit: RMB

Item of Consolidated Balance Sheet	Closing balance	Opening balance	Year-on-year change (%)	Reasons
Derivative financial assets	419,531.82	37,053,847.99	-98.87	Revaluation impairment of outstanding foreign currency forward contracts at the end of the Reporting Period.
Note receivables	21,468,608.63	2,708,500.00	692.64	Note receivables increased during the Reporting Period.
Trade receivables	2,982,196,901.99	1,994,688,445.37	49.51	Trade receivables increased in line with the increase in revenue during the Reporting Period.
Other receivables	42,737,519.34	89,329,521.77	-52.16	Receivables due to equity transfer were settled during the Reporting Period.
Inventories	1,263,339,748.59	952,473,377.38	32.64	Raw materials and goods in progress increased resulted from the increase in orders during the Reporting Period. There was also an addition of consumable biological assets during the same period.
Long-term equity investments	928,430,181.29	655,557,675.24	41.62	Long-term equity investment increased mainly due to the gain from equity interest in WuXi Healthcare Ventures II L.P.
Other non-current financial assets	3,657,691,962.08	2,079,310,692.63	75.91	During the Reporting Period, the Company conducted equity investment in companies of medical examination and health management service and medical equipment business.
Productive biological assets	77,489,000.00	—	N/A	During the Reporting Period, the Company newly established a subsidiary to purchase biological assets for experiments. The productive biological assets are accounted at fair value on the purchase day.

<b>Item of Consolidated Balance Sheet</b>	<b>Closing balance</b>	<b>Opening balance</b>	<b>Year-on-year change (%)</b>	<b>Reasons</b>
Right-of-use assets	769,385,461.00	—	N/A	During the Reporting Period, right-of-use assets of operating leases were recognized under the PRC Accounting Standards for Business Enterprises No. 21 — Leases.
Short-term borrowings	1,403,699,470.17	120,000,000.00	1,069.75	New borrowings were raised to finance working capital and various investment projects during the Reporting Period.
Financial liabilities held for trading	18,112,959.69	—	N/A	Contingent consideration for the acquisition of a subsidiary, Pharmapace, Inc., during the Reporting Period.
Derivative financial liabilities	291,531,390.24	153,292,270.18	90.18	Revaluation impairment of fair value of outstanding foreign currency forward contracts as at the end of the Reporting Period.
Trade payables	519,253,214.30	379,361,422.80	36.88	Trade payables increased in line with the increase in inventories during the Reporting Period.
Non-current liabilities due within one year	109,038,205.41	234,808,155.17	-53.56	Payment for the purchase of Wuhan facilities was made during the Reporting Period. In addition, rental liabilities due within one year were recognized under the PRC Accounting Standards for Business Enterprises No. 21 — Leases.
Long-term borrowings	815,000,000.00	15,000,000.00	5,333.33	New borrowings were raised to finance various investment projects during the Reporting Period.
Bond payables	1,883,488,915.03	—	N/A	Overseas zero coupon convertible bonds due 2024 were issued during the Reporting Period. See Note 1 for details.

Item of Consolidated Balance Sheet	Closing balance	Opening balance	Year-on-year change (%)	Reasons
Rental liabilities	736,295,692.14	—	N/A	During the Reporting Period, operating rental liabilities were recognized under the PRC Accounting Standards for Business Enterprises No. 21 — Leases.
Deferred income	548,052,269.90	418,842,935.80	30.85	Government subsidies increased during the Reporting Period.
Deferred tax liabilities	161,483,381.12	111,747,212.22	44.51	Higher deferred tax liabilities were recognized on intangible assets arising from the acquisition of a subsidiary, Pharmapace, Inc., during the Reporting Period.
Other non-current liabilities	312,072,569.02	194,323,218.12	60.59	The Group issued convertible bonds during the Reporting Period. The conversion options of convertible bonds were recognized as derivative instruments and were included in this item. In addition, deferred rental previously included in this item was reclassified as rental liabilities under the PRC Accounting Standards for Business Enterprises No. 21 — Leases during the Reporting Period.
Paid-in capital (or share capital)	1,637,704,965.00	1,164,741,086.00	40.61	The Group raised funds through the over-allotment of H Shares in January 2019. Capital reserve was capitalized for the issue of four bonus Shares for every ten Shares executed under the 2018 Profit Distribution Plan in July 2019.
Minority interests	93,024,681.64	477,209,988.27	-80.51	The proportion of minority interests decreased during the Reporting Period due to the acquisition of the minority interests in a subsidiary, STA.



*Note 1:* The Group issued overseas zero coupon convertible bonds due 2024 with an aggregate principal amount of USD\$300 million on September 17, 2019. The conversion period is from October 28, 2019 onwards up to the close of business on the date falling 10 days prior to the maturity date. The initial conversion price of HK\$111.80 per H Share will be subject to adjustments under certain circumstances.

The convertible bonds were initially recognized at fair value upon issuance. The convertible bonds issued by the Group which contain liabilities and conversion options, were split upon initial recognition. The embedded derivative financial instruments of the convertible bonds were recognized at fair value of US\$28,650,000 (equivalent to RMB202,638,585.00) as derivative financial instruments and recorded in other non-current liabilities. The issue price in excess of the portion initially recognized as derivative financial instruments of US\$271,350,000 (equivalent to RMB1,919,231,415.00), was recognized as debt instruments.

In the subsequent measurement, the derivative financial instruments shall be measured at fair value through profit or loss; the liability component of the convertible bonds shall be measured at the amortized cost using the effective interest method.

Trading fees incurred from the issuance of convertible bonds shall be allocated between liabilities and derivative financial instruments at their respective fair values. Trading fees in relation to the derivative financial instruments shall be accounted for in profit or loss, whereas trading fees in relation to liabilities shall be accounted for at the carrying value of the liabilities and amortized over the period of the convertible bonds using effective interest method.

Unit: RMB

Item of Consolidated Cash Flow Statement	From the beginning of the year to the end of the Reporting Period (January — September)	From the beginning of last year to the end of the reporting period of last year (January — September)	Change (%)	Reasons
Net cash flow generated from operating activities	1,773,185,018.60	917,299,030.50	93.31	The increase was due primarily to a strong growth of all business segments, resulting in increased cash generated from sales of goods and services, net with cash payment for goods and services and cash paid to and for employees; a decrease in cash outflow of tax payment over the Reporting Period (mainly due to the decreasing payment of the taxes arising from intragroup asset transfer of Pharmaceutical Development Service Department from WXAT Shanghai to STA in 2017); and an increase in cash inflow of government subsidiaries received over the Reporting Period.
Net cash flow used in investment activities	-3,899,946,133.25	-4,590,197,969.81	N/A	The decrease was mainly due to a decrease in cash payment of financial products and equity investment over the Reporting Period, which was offset by an increase in cash paid for purchasing biological assets for experiments.
Net cash flow generated from financing activities	1,003,167,883.97	2,123,905,932.82	-52.77	The decrease was mainly due to an increase in cash outflow as a result of acquiring minority interests of STA, a subsidiary of the Company, and payment of cash dividend; and a decrease in cash inflow from proceeds upon partial exercise of H Shares over-allotment option in 2019 as compared to the cash inflow from proceeds of A Shares during the corresponding period of the previous year, which was offset by an increase of cash inflow from issuing overseas zero coupon convertible bonds and an increase of net borrowings.

### **3.2 Analysis and explanations of the progress of significant events and their impacts and solutions**

✓ Applicable     Not applicable

#### ***1. IMPLEMENTATION OF THE 2018 PROFIT DISTRIBUTION PLAN***

The Company implemented the 2018 Profit Distribution Plan on July 2, 2019 pursuant to the 2018 Profit Distribution Plan considered and approved at the annual general meeting for 2018, the first A Share class meeting for 2019 and the first H Share class meeting for 2019 held on June 3, 2019. Upon the distribution, total share capital of the Company was 1,638,043,314 Shares, of which 1,467,529,754 were A Shares. For details of cash dividend for holders of H Shares, please refer to relevant announcements published by the Company on the website of the Stock Exchange ([www.hkexnews.hk](http://www.hkexnews.hk)) on June 3, 2019, June 13, 2019 and June 18, 2019, respectively.

#### ***2. ADJUSTMENT TO THE AMOUNT OF RESERVED INTERESTS UNDER THE RESTRICTED A SHARES AND STOCK OPTION INCENTIVE PLAN OF 2018 AND GRANT OF RESERVED INTERESTS TO PARTICIPANTS***

The Company considered and approved the Resolution on Adjustment to the Amount of Reserved Interests under the Restricted A Shares and Stock Option Incentive Plan of 2018 at the 32nd meeting of the first session of the board of directors and the 20th meeting of the first session of the Supervisory Committee held on July 19, 2019, and agreed to adjust the amount of reserved interests under the Restricted A Shares and Stock Option Incentive Plan of 2018. After the adjustment, the amount of reserved interests was changed from 1,771,400 units to 2,479,960 units. On the same date, the Board of Directors and the Supervisory Committee considered and approved the Resolution on Grant of Reserved Interests to Participants. The Board of Directors agreed that the date of the grant of reserved interests under the Restricted A Shares and Stock Option Incentive Plan of 2018 shall be July 19, 2019. Pursuant to the Restricted A Shares and Stock Option Incentive Plan of 2018 resolved, 542,017 Restricted A Shares were granted to 21 participants at the price of RMB32.44 per Share and 287,000 share options were granted to 2 participants at the exercise price of RMB64.88 per Share.

**3. ADJUSTMENT TO THE REPURCHASE NUMBER AND REPURCHASE PRICE AND THE REPURCHASE AND CANCELLATION OF CERTAIN RESTRICTED SHARES ISSUED TO PARTICIPANTS**

The Company considered and approved the Proposal on Adjustment to the Repurchase Number and Repurchase Price of Restricted A Shares and the Resolution on the Repurchase and Cancellation of Certain Restricted Shares Issued under the Restricted A Shares and Stock Option Incentive Plan of 2018 at the 32nd meeting of the first session of the board of directors and the 20 meeting of the first session of the Supervisory Committee held on July 19, 2019. Pursuant to the above proposals, due to the resignation of certain participants and the completion of the 2018 Profit Distribution Plan, the Company intended to repurchase and cancel Restricted A Shares which have been issued to such participants with adjustment to the repurchase number and repurchase price. A total of 338,349 Restricted A Shares shall be repurchased after adjustment at an adjusted repurchased price of RMB32.15 per Share.

**4. LISTING OF US\$300 MILLION ZERO COUPON CONVERTIBLE BONDS DUE 2024 ON THE STOCK EXCHANGE**

The issuance of US\$300 million zero coupon convertible bonds due 2024 (the “Convertible Bonds”) of the Company, the application for which had been made to the Stock Exchange, was completed on September 17, 2019. The listing of and permission to deal in the Convertible Bonds became effective on September 18, 2019. The Convertible Bonds were issued to professional investors (as defined in Chapter 37 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited) pursuant to the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) and relevant regulations only.

**5. GRANT OF SHARE APPRECIATION RIGHTS TO THE PARTICIPANTS**

The Company considered and approved the Resolution on Grant of Share Appreciation Rights to the Participants at the 34th meeting of the first session of the Board of Directors and the 22nd meeting of the first session of the Supervisory Committee held on September 30, 2019. The Board of Directors confirmed September 30, 2019 as the grant date and granted 2,901,172 Share Appreciation Rights to 234 Incentive Participants.

## **6. 2019 A SHARE INCENTIVE PLAN (PROPOSAL)**

The Company considered and approved the 2019 A Share Incentive Plan (Proposal) and its summary at the first extraordinary general meeting for 2019, the second A Share class meeting for 2019 and the second H Share class meeting for 2019 held on September 20, 2019. An aggregate of 21,055,530 units are proposed to be granted to the Incentive Participants, as ordinary A Shares dominated in RMB. Among which, 13,657,803 Restricted A Shares and 5,292,174 Share Options shall be granted initially, representing 90% of the total interests to be granted. Reserved interests (which may also be granted as Restricted A Shares or Share Options) amount to 2,105,553 units, representing 10% of the total interests to be granted.

### **3.3 Undertakings not performed during the Reporting Period**

Applicable     Not applicable

### **3.4 Caution and explanation as to the anticipated loss of accumulated net profit from the beginning of the year to the end of the next reporting period or significant changes over the same period of last year**

Applicable     Not applicable

Name of Company	WuXi AppTec Co., Ltd.
Legal representative	Ge Li
Date	October 30, 2019

## IV. Appendix

### 4.1 Financial Statement

#### Consolidated Balance Sheet

As at September 30, 2019

Prepared by: WuXi AppTec Co., Ltd.

Item	<i>Unit: RMB Type of audit: Unaudited</i>	
	As at September 30, 2019	As at December 31, 2018
<b>Current Assets:</b>		
Bank balances and cash	4,642,612,561.35	5,760,604,147.14
Financial assets held for trading	2,523,680,190.68	2,125,333,652.33
Derivative financial assets	419,531.82	37,053,847.99
Note receivables	21,468,608.63	2,708,500.00
Trade receivables	2,982,196,901.99	1,994,688,445.37
Prepayments	90,899,509.81	78,279,297.10
Other receivables	42,737,519.34	89,329,521.77
Including: Interest receivables	4,010,502.42	1,297,144.52
Dividend receivables	—	—
Inventories	1,263,339,748.59	952,473,377.38
Contract assets	301,343,279.74	384,530,263.19
Other current assets	435,600,458.85	381,600,095.06
Total Current Assets	<u>12,304,298,310.80</u>	<u>11,806,601,147.33</u>
<b>Non-current Assets:</b>		
Long-term equity investments	928,430,181.29	655,557,675.24
Other non-current financial assets	3,657,691,962.08	2,079,310,692.63
Fixed assets	3,981,719,718.49	3,491,176,791.95
Construction in progress	1,975,279,787.69	1,526,983,398.38
Productive biological assets	77,489,000.00	—
Right-of-use assets	769,385,461.00	—
Intangible assets	771,484,222.62	626,492,472.61
Goodwill	1,262,591,953.67	1,144,075,895.78
Long-term deferred expenditures	1,286,715,589.00	1,039,582,358.15
Deferred tax assets	298,482,591.43	250,174,757.91
Other non-current assets	56,837,912.25	47,246,710.83
Total Non-current Assets	<u>15,066,108,379.52</u>	<u>10,860,600,753.48</u>
Total Assets	<u><u>27,370,406,690.32</u></u>	<u><u>22,667,201,900.81</u></u>

Item	As at September 30, 2019	As at December 31, 2018
<b>Current Liabilities:</b>		
Short-term borrowings	1,403,699,470.17	120,000,000.00
Financial liabilities held for trading	18,112,959.69	—
Derivative financial liabilities	291,531,390.24	153,292,270.18
Note payables	19,522,542.49	19,362,968.27
Trade payables	519,253,214.30	379,361,422.80
Payroll payables	538,764,549.93	548,388,970.23
Tax payables	257,842,639.78	203,924,217.76
Other payables	1,686,022,604.73	1,418,046,171.41
Including: Interest payables	6,772,727.13	166,055.54
Dividend payables	—	—
Contract liabilities	757,323,033.39	681,863,412.40
Non-current liabilities due within one year	109,038,205.41	234,808,155.17
Other current liabilities	717,851.82	3,010,136.90
	<hr/>	<hr/>
Total Current Liabilities	5,601,828,461.95	3,762,057,725.12
	<hr/>	<hr/>
<b>Non-current Liabilities:</b>		
Long-term borrowings	815,000,000.00	15,000,000.00
Bond payables	1,883,488,915.03	—
Including: Preference shares	—	—
Perpetual bonds	—	—
Rental liabilities	736,295,692.14	—
Deferred income	548,052,269.90	418,842,935.80
Deferred tax liabilities	161,483,381.12	111,747,212.22
Other non-current liabilities	312,072,569.02	194,323,218.12
	<hr/>	<hr/>
Total Non-current Liabilities	4,456,392,827.21	739,913,366.14
	<hr/>	<hr/>
Total Liabilities	10,058,221,289.16	4,501,971,091.26
	<hr/>	<hr/>

Item	As at September 30, 2019	As at December 31, 2018
<b>Owners' Equity (or Shareholders' Equity)</b>		
Paid-in capital (or share capital)	1,637,704,965.00	1,164,741,086.00
Capital reserve	9,918,485,829.96	11,977,422,142.52
Less: Treasury shares	271,002,913.97	285,988,954.90
Other comprehensive income	100,320,881.16	56,291,730.54
Surplus reserve	87,709,227.10	87,709,227.10
Undistributed profit	<u>5,745,942,730.27</u>	<u>4,687,845,590.02</u>
Total Equity (or Shareholders' Equity) attributable to owners of the parent company	17,219,160,719.52	17,688,020,821.28
Minority interests	<u>93,024,681.64</u>	<u>477,209,988.27</u>
Total Owners' Equity (or Shareholders' Equity)	<u>17,312,185,401.16</u>	<u>18,165,230,809.55</u>
Total Liabilities and Owners' Equity (or Shareholders' Equity)	<u><u>27,370,406,690.32</u></u>	<u><u>22,667,201,900.81</u></u>
Legal Representative:	Ge Li	
Chief Financial Officer:	Ellis Bih-Hsin Chu	
Director of the Accounting Department:	Jin Sun	



## Balance Sheet of the Parent Company

As at September 30, 2019

Prepared by: WuXi AppTec Co., Ltd.

Item	<i>Unit: RMB Type of audit: Unaudited</i>	
	As at September 30, 2019	As at December 31, 2018
<b>Current Assets:</b>		
Bank balance and cash	3,415,005,499.29	4,472,837,985.45
Financial assets held for trading	609,333,007.65	570,723,837.61
Prepayments	366,340.06	1,326,089.58
Other receivables	2,382,347,627.72	2,204,369,610.09
Including: Interest receivables	4,008,253.24	1,297,144.52
Dividend receivables	282,651,826.39	782,651,826.39
Other current assets	7,407,092.51	10,110,894.94
Total Current Assets	<u>6,414,459,567.23</u>	<u>7,259,368,417.67</u>
<b>Non-current Assets:</b>		
Long-term equity investments	8,717,499,165.89	6,006,473,541.02
Construction in progress	1,440,000.00	—
Intangible assets	91,467,218.76	90,500,000.00
Total Non-current Assets	<u>8,810,406,384.65</u>	<u>6,096,973,541.02</u>
Total Assets	<u><u>15,224,865,951.88</u></u>	<u><u>13,356,341,958.69</u></u>

<b>Item</b>	<b>As at September 30, 2019</b>	<b>As at December 31, 2018</b>
<b>Current Liabilities:</b>		
Payroll payables	141,346.79	9,113,732.05
Tax payables	25,876,627.02	1,458,557.54
Other payables	327,399,782.95	358,686,709.73
Including: Interest payables	—	—
Dividend payables	—	—
	<hr/>	<hr/>
Total Current Liabilities	<u>353,417,756.76</u>	<u>369,258,999.32</u>
<b>Non-current Liabilities:</b>		
Bond payables	1,883,488,915.03	—
Including: Preference Shares	—	—
Perpetual bonds	—	—
Other non-current liabilities	202,638,585.00	—
	<hr/>	<hr/>
Total Non-current Liabilities	<u>2,086,127,500.03</u>	—
Total Liabilities	<u>2,439,545,256.79</u>	<u>369,258,999.32</u>
<b>Owners' Equity (or Shareholders' Equity)</b>		
Paid-in capital (or share capital)	1,637,704,965.00	1,164,741,086.00
Capital reserve	11,154,491,235.09	11,245,781,385.46
Less: Treasury shares	271,002,913.97	285,988,954.90
Surplus reserve	87,709,227.10	87,709,227.10
Undistributed profit	176,418,181.87	774,840,215.71
	<hr/>	<hr/>
Total Owner's Equity (or Shareholders' equity)	<u>12,785,320,695.09</u>	<u>12,987,082,959.37</u>
Total Liabilities and Owners' Equity (or Shareholders' Equity)	<u><u>15,224,865,951.88</u></u>	<u><u>13,356,341,958.69</u></u>
Legal Representative:	Ge Li	
Chief Financial Officer:	Ellis Bih-Hsin Chu	
Director of the Accounting Department:	Jin Sun	

## Consolidated Income Statement

January to September 2019

Prepared by: WuXi AppTec Co., Ltd.

		<i>Unit: RMB Type of audit: Unaudited</i>			
Item	Third quarter of 2019 (July — September)	Third quarter of 2018 (July — September)	First three quarters of 2019 (January — September)	First three quarters of 2018 (January — September)	
I. Total revenue	3,384,155,804.66	2,511,927,822.68	9,278,514,251.38	6,921,135,001.68	
Including: Revenue	3,384,155,804.66	2,511,927,822.68	9,278,514,251.38	6,921,135,001.68	
II. Total cost	2,539,091,079.67	1,951,544,463.24	7,288,072,146.07	5,428,790,825.83	
Including: Cost	2,004,453,094.76	1,462,832,305.49	5,612,735,942.99	4,105,515,828.51	
Taxes and surcharges	4,420,243.64	5,219,432.12	19,866,202.71	22,242,713.62	
Selling and marketing expenses	104,661,434.58	80,336,849.42	313,174,962.20	233,016,820.00	
Administrative expenses	372,185,300.85	340,125,563.79	1,028,463,979.83	767,659,847.16	
Research and development expenses	170,696,987.34	119,479,914.24	414,319,379.97	297,004,655.82	
Finance expenses	-117,325,981.50	-56,449,601.82	-100,488,321.63	3,350,960.72	
Including: Interest expense	25,426,485.53	23,430,883.03	41,229,366.95	68,951,866.02	
Interest income	12,719,911.75	3,436,642.63	64,563,264.19	9,133,329.83	
Add: Other income	34,949,234.93	15,674,837.04	103,553,177.55	51,278,911.07	
Investment gains (losses are represented by “-”)	73,655,335.10	-23,157,563.96	199,593,997.90	36,451,586.77	
Including: Gains from investments in associates and joint ventures	52,160,865.23	-19,012,478.05	104,937,141.53	10,887,582.57	
Gains from changes in fair value (“-” indicating loss)	-77,783,461.98	208,778,840.80	-132,176,799.62	590,231,365.46	
Credit impairment losses (“-” indicating loss)	-8,886,650.83	-5,805,918.17	-10,038,827.73	-157,534.33	
Assets impairment losses (“-” indicating loss)	-1,650,787.38	-2,343,763.08	-1,025,136.30	-972,558.41	
Gains on assets disposal (“-” indicating loss)	-1,038,817.09	-23,240.29	1,035,391.87	-310,528.26	

	<b>Item</b>	<b>Third quarter of 2019 (July — September)</b>	<b>Third quarter of 2018 (July — September)</b>	<b>First three quarters of 2019 (January — September)</b>	<b>First three quarters of 2018 (January — September)</b>
III.	Operating profit ("—" indicating loss)	864,309,577.74	753,506,551.78	2,151,383,908.98	2,168,865,418.15
	Add: Non-operating income	368,516.31	1,465,759.63	1,342,760.21	14,591,580.22
	Less: Non-operating expenses	177,719.61	1,273,445.08	6,759,572.67	4,727,298.25
IV.	Total profit ("—" indicating total loss)	864,500,374.44	753,698,866.33	2,145,967,096.52	2,178,729,700.12
	Less: Income tax expense	151,041,366.29	78,600,560.09	327,543,076.13	199,561,718.38
V.	Net profit ("—" indicating net loss)	713,459,008.15	675,098,306.24	1,818,424,020.39	1,979,167,981.74
(I)	Classified by continuity of operations				
1.	Net profit from continuing operations ("—" indicating net loss)	713,459,008.15	675,098,306.24	1,818,424,020.39	1,979,167,981.74
2.	Net profit from discontinued operations ("—" indicating net loss)	—	—	—	—
(II)	Classified by ownership				
1.	Net profit attributable to owners of the parent company ("—" indicating net loss)	708,384,430.87	656,479,057.10	1,765,146,773.87	1,928,376,253.99
2.	Profit attributable to minority shareholders ("—" indicating net loss)	5,074,577.28	18,619,249.14	53,277,246.52	50,791,727.75

		Third quarter of 2019 (July — September)	Third quarter of 2018 (July — September)	First three quarters of 2019 (January — September)	First three quarters of 2018 (January — September)
VI.	Other comprehensive income, net of tax	-8,336,848.05	-22,960,879.19	47,275,770.54	-45,589,693.56
	Other comprehensive income attributable to owners of the parent company, net of tax	-7,919,136.41	-9,203,182.12	44,029,150.62	-36,320,814.43
(I)	Other comprehensive income that will not be reclassified to profit or loss	—	—	—	—
(II)	Other comprehensive income that will be reclassified to profit or loss	-7,919,136.41	-9,203,182.12	44,029,150.62	-36,320,814.43
1.	Other comprehensive income that will be transferred to profit or loss accounted for using equity method	—	—	—	—
2.	Changes in fair value of other debt investments	—	—	—	—
3.	Gain or loss on changes in fair value of available-for-sale financial assets	—	—	—	—
4.	Financial assets reclassified to other comprehensive income	—	—	—	—
5.	Gain or loss on reclassification of held-to-maturity investments to available-for-sale financial assets	—	—	—	—
6.	Credit impairment allowance of other debt investments	—	—	—	—

Item	Third quarter of 2019 (July — September)	Third quarter of 2018 (July — September)	First three quarters of 2019 (January — September)	First three quarters of 2018 (January — September)
7. Cash flow hedging reserve (effective portion of cash flow adjusted for hedging gain or loss)	-98,587,786.55	-75,982,262.68	-51,336,658.65	-141,866,356.36
8. Exchange difference on translation of foreign financial statements	90,668,650.14	66,779,080.56	95,365,809.27	105,545,541.93
9. Others	—	—	—	—
Other comprehensive income attributable to minority shareholders, net of tax	-417,711.64	-13,757,697.07	3,246,619.92	-9,268,879.13
VII. Total comprehensive income	705,122,160.10	652,137,427.05	1,865,699,790.93	1,933,578,288.18
Total comprehensive income attributable to owners of the parent company	700,465,294.46	647,275,874.98	1,809,175,924.49	1,892,055,439.56
Total comprehensive income attributable to minority shareholders	4,656,865.64	4,861,552.07	56,523,866.44	41,522,848.62
VIII. Earnings per share:				
(I) Basic earnings per share (RMB per share)	0.43	0.46	1.08	1.39
(II) Diluted earnings per share (RMB per share)	0.43	0.45	1.07	1.38

For the business combination involving enterprises under common control during the Reporting Period, realised net profit of the merged parties before the merger was RMB0.00 (corresponding period of the previous year: RMB0.00).

Legal Representative:	Ge Li
Chief Financial Officer:	Ellis Bih-Hsin Chu
Director of the Accounting Department:	Jin Sun

## Income Statement of the Parent Company

January to September 2019

Prepared by: WuXi AppTec Co., Ltd.

		<i>Unit: RMB Type of audit: Unaudited</i>			
Item	Third quarter of 2019 (July — September)	Third quarter of 2018 (July — September)	First three quarters of 2019 (January — September)	First three quarters of 2018 (January — September)	
I. Revenue	—	—	—	—	
Less: Cost	—	—	—	—	
Taxes and surcharges	55,053.08	—	1,872,556.45	—	
Selling and marketing expenses	—	—	—	17,500.00	
Administrative expenses	13,751,788.92	8,433,743.73	31,755,679.87	18,913,115.51	
Finance expenses	-86,182,157.74	-6,936,592.20	-123,460,118.39	-7,975,375.64	
Including: Interest expenses	6,694,900.03	2,565.76	6,694,900.03	8,726.54	
Interest income	9,794,126.48	6,412,827.47	68,943,368.79	12,320,050.58	
Add: Other income	69,593.35	1,000,000.00	1,076,713.64	1,000,000.00	
Investment gains	5,407,293.75	7,930,937.98	13,840,730.57	14,890,116.29	
(“-” indicating loss)					
Including: Gains from investments in associates and joint ventures	—	—	—	—	
Gains from changes in fair value (“-” indicating loss)	-40,132.21	—	1,509,170.04	—	
Gains on assets disposal (“-” indicating loss)	—	-509.80	—	8,496.20	
II. Operating profit (“-” indicating loss)	77,812,070.63	7,433,276.65	106,258,496.32	4,943,372.62	
Add: Non-operating income	—	—	—	3,095,337.61	
Less: Non-operating expenses	—	—	—	—	
III. Total profit (“-” indicating total loss)	77,812,070.63	7,433,276.65	106,258,496.32	8,038,710.23	
Less: Income tax expenses	19,784,316.15	1,858,319.16	26,038,962.67	2,037,976.53	

Item	Third quarter of 2019 (July — September)	Third quarter of 2018 (July — September)	First three quarters of 2019 (January — September)	First three quarters of 2018 (January — September)
IV. Net profit (“-” indicating net loss)	58,027,754.48	5,574,957.49	80,219,533.65	6,000,733.70
(I) Net profit from continuing operations (“-” indicating net loss)	58,027,754.48	5,574,957.49	80,219,533.65	6,000,733.70
(II) Net profit from discontinued operations (“-” indicating net loss)	—	—	—	—
V. Other comprehensive income (net of tax)	—	—	—	—
VI. Total comprehensive income	58,027,754.48	5,574,957.49	80,219,533.65	6,000,733.70
VII. Earnings per share:				
(I) Basic earnings per share (RMB per share)	N/A	N/A	N/A	N/A
(II) Diluted earnings per share (RMB per share)	N/A	N/A	N/A	N/A

Legal Representative:	Ge Li
Chief Financial Officer:	Ellis Bih-Hsin Chu
Director of the Accounting Department:	Jin Sun



## Consolidated Cash Flow Statement

January to September 2019

Prepared by: WuXi AppTec Co., Ltd.

Item	<i>Unit: RMB Type of audit: Unaudited</i>	
	First three quarters of 2019 (January — September)	First three quarters of 2018 (January — September)
<b>I. Cash flow from operating activities:</b>		
Cash received from sale of goods or rendering of services	8,682,845,176.38	6,587,023,633.52
Refunds of taxes and surcharges	265,376,801.69	189,473,959.80
Cash received relating to other operating activities	438,253,715.48	93,820,090.80
	<hr/>	<hr/>
Sub-total of cash inflow generated from operating activities	9,386,475,693.55	6,870,317,684.12
	<hr/>	<hr/>
Cash paid for purchasing goods and receiving services	3,559,056,647.35	2,687,566,662.00
Cash paid to and on behalf of employees	3,010,928,564.97	1,974,299,324.79
Payments of taxes and surcharges	371,629,062.58	594,051,817.50
Cash paid relating to other operating activities	671,676,400.05	697,100,849.33
	<hr/>	<hr/>
Sub-total of cash outflow used in operating activities	7,613,290,674.95	5,953,018,653.62
	<hr/>	<hr/>
Net cash flow generated from operating activities	1,773,185,018.60	917,299,030.50
	<hr/>	<hr/>

Item	First three quarters of 2019 (January — September)	First three quarters of 2018 (January — September)
<b>II. Cash flow from investing activities:</b>		
Cash received from disposal of investments	88,297,480.00	79,845,809.76
Cash received from return on investments	125,321,830.33	76,376,356.85
Net cash received from disposal of fixed assets, intangible assets and other long- term assets	8,516,545.92	3,562,073.45
Net cash received from disposal of subsidiaries and other business entities	—	23,788,656.80
Cash received relating to other investing activities	—	—
	<hr/>	<hr/>
Sub-total of cash inflow generated from investing activities	222,135,856.25	183,572,896.86
	<hr/>	<hr/>
Cash paid to acquire fixed assets, intangible assets and other long-term assets	1,831,514,200.42	1,278,961,303.93
Cash paid to acquire investments	2,160,319,258.63	3,494,809,562.74
Net cash paid to acquire subsidiaries and other business entities	130,248,530.45	—
Cash paid relating to other investing activities	—	—
	<hr/>	<hr/>
Sub-total of cash outflow used in investing activities	4,122,081,989.50	4,773,770,866.67
	<hr/>	<hr/>
Net cash flow used in investing activities	-3,899,946,133.25	-4,590,197,969.81
	<hr/>	<hr/>

Item	First three quarters of 2019 (January — September)	First three quarters of 2018 (January — September)
<b>III. Cash flow from financing activities:</b>		
Cash received from capital contributions:	333,018,425.12	2,160,661,257.22
Including: Cash received from capital contribution by minority shareholders of subsidiaries	—	—
Cash received from borrowings	2,194,936,329.76	1,333,197,600.00
Cash received from bond issuance	2,083,882,461.21	—
Cash received relating to other financing activities	—	25,863,619.00
	<hr/>	<hr/>
Sub-total of cash inflow generated from financing activities	4,611,837,216.09	3,519,722,476.22
	<hr/>	<hr/>
Cash repayments of borrowings	120,000,000.00	1,068,165,000.00
Cash payments for distribution of dividends, profits or interest expenses	701,515,172.22	79,131,436.20
Including: Dividends and profits paid by subsidiaries to minority shareholders	—	19,205,387.83
Cash paid relating to other financing activities	2,787,154,159.90	248,520,107.20
	<hr/>	<hr/>
Sub-total of cash outflow used in financing activities	3,608,669,332.12	1,395,816,543.40
	<hr/>	<hr/>
Net cash flow generated from financing activities	1,003,167,883.97	2,123,905,932.82
	<hr/>	<hr/>
<b>IV. Effect of fluctuations in exchange rates on cash and cash equivalents</b>	4,298,579.44	6,488,535.29
	<hr/>	<hr/>
<b>V. Net decrease in cash and cash equivalents</b>	-1,119,294,651.24	-1,542,504,471.20
Add: Balance of cash and cash equivalents at the beginning of the period	5,757,690,780.22	2,466,143,803.49
	<hr/>	<hr/>
<b>VI. Balance of cash and cash equivalents at the end of the period</b>	<u>4,638,396,128.98</u>	<u>923,639,332.29</u>

Legal Representative:	Ge Li
Chief Financial Officer:	Ellis Bih-Hsin Chu
Director of the Accounting Department:	Jin Sun

## Cash Flow Statement of the Parent Company

January to September 2019

Prepared by: WuXi AppTec Co., Ltd.

Item	<i>Unit: RMB Type of audit: Unaudited</i>	
	First three quarters of 2019 (January — September)	First three quarters of 2018 (January — September)
<b>I. Cash flow from operating activities:</b>		
Cash received from sale of goods or rendering of services	—	—
Refunds of taxes and surcharges	—	—
Cash received relating to other operating activities	54,279,898.59	5,951,243.93
Sub-total of cash inflow generated from operating activities	54,279,898.59	5,951,243.93
Cash paid for purchasing goods and receiving services	—	—
Cash paid to and on behalf of employees	21,106,476.27	18,288,049.69
Payments of taxes and surcharges	1,872,556.45	15,181,676.46
Cash paid relating to other operating activities	7,716,246.34	13,190,458.13
Sub-total of cash outflow used in operating activities	30,695,279.06	46,660,184.28
Net cash flow generated from/(used in) operating activities	23,584,619.53	-40,708,940.35

<b>Item</b>	<b>First three quarters of 2019 (January — September)</b>	<b>First three quarters of 2018 (January — September)</b>
<b>II. Cash flows from investment activities:</b>		
Cash received from disposal of investments	—	—
Cash received from return on investments	513,840,730.57	172,668,136.90
Net cash received from disposal of fixed assets, intangible assets and other long-term assets	—	—
Net cash received from disposal of subsidiaries and other business entities	—	—
Cash received relating to other investing activities	<u>1,645,696,823.74</u>	<u>367,878,092.54</u>
Sub-total of cash inflow generated from investing activities	<u>2,159,537,554.31</u>	<u>540,546,229.44</u>
Cash paid to acquire fixed assets, intangible assets and other long-term assets	3,620,660.38	—
Cash paid to acquire investments	2,666,366,984.01	1,837,738,838.75
Net cash paid to acquire subsidiaries and other business entities	—	—
Cash paid relating to other investing activities	<u>2,235,678,959.92</u>	<u>895,873,404.48</u>
Sub-total of cash outflow used in investing activities	<u>4,905,666,604.31</u>	<u>2,733,612,243.23</u>
Net cash flow used in investing activities	<u>-2,746,129,050.00</u>	<u>-2,193,066,013.79</u>

Item	First three quarters of 2019 (January — September)	First three quarters of 2018 (January — September)
<b>III. Cash flow from financing activities:</b>		
Cash received from investments	323,767,915.19	2,160,661,257.22
Cash received from borrowings	—	—
Cash received from bond issuance	2,083,882,461.21	—
Cash received relating to other financing activities	—	—
	<hr/>	<hr/>
Sub-total of cash inflow generated from financing activities	2,407,650,376.40	2,160,661,257.22
	<hr/>	<hr/>
Cash repayments of borrowings	—	—
Cash payments for distribution of dividends, profits or interest expenses	678,641,317.31	—
Cash paid relating to other financing activities	52,341,464.42	19,286,009.36
	<hr/>	<hr/>
Sub-total of cash outflow used in financing activities	730,982,781.73	19,286,009.36
	<hr/>	<hr/>
Net cash flow generated from financing activities	1,676,667,594.67	2,141,375,247.86
	<hr/>	<hr/>
<b>IV. Effect of fluctuations in exchange rates on cash and cash equivalents</b>	-11,955,650.36	—
	<hr/>	<hr/>
<b>V. Net decrease in cash and cash equivalents</b>	-1,057,832,486.16	-92,399,706.28
Add: Balance of cash and cash equivalents at the beginning of the period	4,472,837,985.45	120,215,347.06
	<hr/>	<hr/>
<b>VI. Balance of cash and cash equivalents at the end of the period</b>	<u>3,415,005,499.29</u>	<u>27,815,640.78</u>

Legal Representative:	Ge Li
Chief Financial Officer:	Ellis Bih-Hsin Chu
Director of the Accounting Department:	Jin Sun

## 4.2 Adjustments on the financial statements at the beginning of the first year of adopting new financial instrument standards, new revenue standards and new leasing standards

✓ Applicable    □ Not applicable

### Consolidated Balance Sheet

Item	Unit: RMB		
	As at December 31, 2018	As at January 1, 2019	Adjustment
<b>Current Assets:</b>			
Bank balances and cash	5,760,604,147.14	5,760,604,147.14	—
Financial assets held for trading	2,125,333,652.33	2,125,333,652.33	—
Derivative financial assets	37,053,847.99	37,053,847.99	—
Note receivables	2,708,500.00	2,708,500.00	—
Trade receivables	1,994,688,445.37	1,994,688,445.37	—
Prepayments	78,279,297.10	78,279,297.10	—
Other receivables	89,329,521.77	89,329,521.77	—
Including: Interest receivables	1,297,144.52	1,297,144.52	—
Inventories	952,473,377.38	952,473,377.38	—
Contract assets	384,530,263.19	384,530,263.19	—
Other current assets	381,600,095.06	381,600,095.06	—
<b>Total Current Assets</b>	<b>11,806,601,147.33</b>	<b>11,806,601,147.33</b>	<b>—</b>
<b>Non-current Assets:</b>			
Long-term equity investments	655,557,675.24	655,557,675.24	—
Other non-current financial assets	2,079,310,692.63	2,079,310,692.63	—
Fixed assets	3,491,176,791.95	3,491,176,791.95	—
Construction in progress	1,526,983,398.38	1,526,983,398.38	—
Right-of-use assets	—	721,325,428.16	721,325,428.16
Intangible assets	626,492,472.61	626,492,472.61	—
Goodwill	1,144,075,895.78	1,144,075,895.78	—
Long-term deferred expenditures	1,039,582,358.15	1,039,582,358.15	—
Deferred tax assets	250,174,757.91	242,941,016.80	-7,233,741.11
Other non-current assets	47,246,710.83	40,418,596.27	-6,828,114.56
<b>Total Non-current Assets</b>	<b>10,860,600,753.48</b>	<b>11,567,864,325.97</b>	<b>707,263,572.49</b>
<b>Total Assets</b>	<b>22,667,201,900.81</b>	<b>23,374,465,473.30</b>	<b>707,263,572.49</b>

Item	As at December 31, 2018	As at January 1, 2019	Adjustment
<b>Current Liabilities:</b>			
Short-term borrowings	120,000,000.00	120,000,000.00	—
Derivative financial liabilities	153,292,270.18	153,292,270.18	—
Note payables	19,362,968.27	19,362,968.27	—
Trade payables	379,361,422.80	379,361,422.80	—
Payroll payables	548,388,970.23	548,388,970.23	—
Tax payables	203,924,217.76	203,924,217.76	—
Other payables	1,418,046,171.41	1,418,046,171.41	—
Including: Interest payables	166,055.54	166,055.54	—
Contract liabilities	681,863,412.40	681,863,412.40	—
Non-current liabilities due within one year	234,808,155.17	396,693,664.81	161,885,509.64
Other current liabilities	3,010,136.90	3,010,136.90	—
<b>Total Current Liabilities</b>	<u>3,762,057,725.12</u>	<u>3,923,943,234.76</u>	<u>161,885,509.64</u>
<b>Non-current Liabilities:</b>			
Long-term borrowings	15,000,000.00	15,000,000.00	—
Rental liabilities	—	629,092,766.99	629,092,766.99
Deferred income	418,842,935.80	418,842,935.80	—
Deferred tax liabilities	111,747,212.22	111,747,212.22	—
Other non-current liabilities	194,323,218.12	140,140,566.84	-54,182,651.28
<b>Total Non-current Liabilities</b>	<u>739,913,366.14</u>	<u>1,314,823,481.85</u>	<u>574,910,115.71</u>
<b>Total Liabilities</b>	<u>4,501,971,091.26</u>	<u>5,238,766,716.61</u>	<u>736,795,625.35</u>



Item	As at December 31, 2018	As at January 1, 2019	Adjustment
<b>Owners' Equity (or Shareholders' Equity):</b>			
Paid-in capital (or share capital)	1,164,741,086.00	1,164,741,086.00	—
Capital reserve	11,977,422,142.52	11,977,422,142.52	—
Less: Treasury shares	285,988,954.90	285,988,954.90	—
Other comprehensive income	56,291,730.54	56,291,730.54	—
Surplus reserve	87,709,227.10	87,709,227.10	—
Undistributed profit	4,687,845,590.02	4,659,437,273.71	-28,408,316.31
Total equity attributable to owners of the parent company (or shareholders' equity)	17,688,020,821.28	17,659,612,504.97	-28,408,316.31
Minority interests	477,209,988.27	476,086,251.72	-1,123,736.55
Total Owners' Equity (or Shareholders' Equity)	18,165,230,809.55	18,135,698,756.69	-29,532,052.86
Total Liabilities and Owners' Equity (or Shareholders' equity)	22,667,201,900.81	23,374,465,473.30	707,263,572.49

Explanation of adjustment of each item:

Applicable  Not applicable

In December 2018, the Ministry of Finance of the People's Republic of China issued the Circular regarding Amendments on the Accounting Standards for Business Enterprises No. 21 — Leases (Cai Kuai [2018] No. 35). Upon the approval of the Board of Directors, the Company announced the adoption of the above revised accounting standards commencing on January 1, 2019. Due to cumulative effect of the first adoption of the above standard, the Group adjusted the opening balance of retained earnings and the amounts of other related items in the financial statements at the beginning of the year (in which this standard is first adopted), where the data of comparable period shall not be adjusted.

The above data is unaudited.

## Balance Sheet of the Parent Company

Unit: RMB

Item	As at December 31, 2018	As at January 1, 2019	Adjustment
<b>Current Assets:</b>			
Bank balances and cash	4,472,837,985.45	4,472,837,985.45	—
Financial assets held for trading	570,723,837.61	570,723,837.61	—
Prepayments	1,326,089.58	1,326,089.58	—
Other receivables	2,204,369,610.09	2,204,369,610.09	—
Including: Interest receivables	1,297,144.52	1,297,144.52	—
Dividend receivables	782,651,826.39	782,651,826.39	—
Other current assets	10,110,894.94	10,110,894.94	—
<b>Total Current Assets</b>	<u>7,259,368,417.67</u>	<u>7,259,368,417.67</u>	—
<b>Non-current Assets:</b>			
Long-term equity investments	6,006,473,541.02	6,006,473,541.02	—
Intangible assets	90,500,000.00	90,500,000.00	—
<b>Total Non-current Assets</b>	<u>6,096,973,541.02</u>	<u>6,096,973,541.02</u>	—
<b>Total Assets</b>	<u><u>13,356,341,958.69</u></u>	<u><u>13,356,341,958.69</u></u>	<u>—</u>
<b>Current Liabilities:</b>			
Payroll payables	9,113,732.05	9,113,732.05	—
Tax payables	1,458,557.54	1,458,557.54	—
Other payables	358,686,709.73	358,686,709.73	—
Including: Interest payables	—	—	—
Dividend payables	—	—	—
<b>Total Current Liabilities</b>	<u>369,258,999.32</u>	<u>369,258,999.32</u>	—
<b>Non-current Liabilities:</b>			
Total non-current liabilities	—	—	—
<b>Total Liabilities</b>	<u>369,258,999.32</u>	<u>369,258,999.32</u>	—

Item	As at December 31, 2018	As at January 1, 2019	Adjustment
<b>Owners' Equity</b>			
<b>(Shareholders' Equity):</b>			
Paid-in capital (or share capital)	1,164,741,086.00	1,164,741,086.00	—
Capital reserve	11,245,781,385.46	11,245,781,385.46	—
Less: Treasury shares	285,988,954.90	285,988,954.90	—
Surplus reserve	87,709,227.10	87,709,227.10	—
Undistributed profit	<u>774,840,215.71</u>	<u>774,840,215.71</u>	—
 Total Owners' Equity (or Shareholders' equity)	 <u>12,987,082,959.37</u>	 <u>12,987,082,959.37</u>	 —
 Total Liabilities and Owners' Equity (or Shareholders' Equity)	 <u><u>13,356,341,958.69</u></u>	 <u><u>13,356,341,958.69</u></u>	 <u>—</u>

Explanation of adjustment of each item:

Applicable  Not applicable

**4.3 Explanation of first adoption of new financial instrument standards and comparative data of retrospective adjustment of the previous reporting period of new leasing standards.**

Applicable  Not applicable

**4.4 Auditor's Report**

Applicable  Not applicable

#### 4.5 Quarterly condensed consolidated financial statements prepared in accordance with IFRSs

### Consolidated Statement of Profit or Loss<sup>1</sup>

January to September 2019

Prepared by: WuXi AppTec Co., Ltd.

	<i>Unit: RMB'000</i>		<i>Type of audit: Unaudited</i>	
	<b>Third quarter of 2019</b>	<b>Third quarter of 2018</b>	<b>First three quarters of 2019</b>	<b>First three quarters of 2018</b>
	<b>(July — September)</b>	<b>(July — September)</b>	<b>(January — September)</b>	<b>(January — September)</b>
<b>Revenue</b>	3,384,156	2,511,928	9,278,514	6,921,135
Cost of services	(2,007,272)	(1,464,737)	(5,618,039)	(4,117,835)
<b>Gross profit</b>	<b>1,376,884</b>	<b>1,047,191</b>	<b>3,660,475</b>	<b>2,803,300</b>
Other income	53,899	33,139	178,772	87,868
Other gains and losses	76,871	270,732	54,378	660,364
Impairment losses under expected credit losses (“ECL”) model, net of reversal	(8,887)	(5,806)	(10,039)	(158)
Selling and marketing expenses	(104,661)	(80,337)	(313,175)	(233,017)
Administrative expenses	(376,706)	(349,297)	(1,047,946)	(784,558)
Research and development expenses	(170,697)	(119,480)	(414,319)	(297,005)
<b>Operating profit</b>	<b>846,703</b>	<b>796,142</b>	<b>2,108,146</b>	<b>2,236,794</b>
Share of profits/(losses) of associates	62,200	(19,095)	135,178	19,557
Share of (losses)/gains of joint ventures	(10,039)	83	(30,241)	(8,669)
Finance costs	(34,363)	(23,431)	(67,116)	(68,952)
<b>Profit before tax</b>	<b>864,500</b>	<b>753,699</b>	<b>2,145,967</b>	<b>2,178,730</b>
Income tax expense	(151,041)	(78,601)	(327,543)	(199,562)
<b>Profit for the period</b>	<b>713,459</b>	<b>675,098</b>	<b>1,818,424</b>	<b>1,979,168</b>
<b>Profit for the period attributable to:</b>				
Owners of the Company	708,384	656,478	1,765,147	1,928,376
Non-controlling interests	5,075	18,620	53,277	50,792
<b>Earnings per share</b> <b>(expressed in RMB per share)</b>				
— Basic	0.43	0.46	1.08	1.39
— Diluted	0.43	0.45	1.07	1.38

<sup>1</sup> Any discrepancies in data below between the total shown and the sum of the amounts listed are due to rounding.

## Consolidated Statement of Financial Position<sup>2</sup>

As at September 30, 2019

Prepared by: WuXi AppTec Co., Ltd.

	<i>Unit: RMB'000    Type of audit: Unaudited</i>	
	<b>As at September 30, 2019</b>	<b>As at December 31, 2018</b>
<b>Non-current Assets</b>		
Property, plant and equipment	7,227,859	6,057,611
Biological assets	77,489	—
Goodwill	1,262,592	1,144,076
Other intangible assets	427,055	347,949
Prepaid lease payments	—	272,306
Interests in associates	895,594	618,736
Interests in joint ventures	32,836	36,822
Deferred tax assets	298,483	250,175
Financial assets at fair value through profit or loss ("FVTPL")	3,657,692	2,079,311
Other non-current assets	72,694	47,378
Right-of-use assets	1,113,815	—
	<hr/>	<hr/>
Total Non-current Assets	15,066,108	10,854,364
<b>Current Assets</b>		
Inventories	1,132,645	854,761
Contract costs	130,695	97,712
Amounts due from related parties	8,109	13,882
Trade and other receivables	3,559,081	2,498,696
Contract assets	301,343	384,530
Prepaid lease payments	—	6,237
Income tax recoverable	5,713	34,028
Financial assets at FVTPL	2,523,680	2,125,334
Derivative financial instruments	420	37,054
Pledged bank deposits	4,216	2,913
Bank balances and cash	4,638,396	5,757,691
	<hr/>	<hr/>
Total Current Assets	12,304,298	11,812,838

<sup>2</sup> Any discrepancies in data below between the total shown and the sum of the amounts listed are due to rounding.

	As at September 30, 2019	As at December 31, 2018
<b>Current Liabilities</b>		
Trade and other payables	2,764,499	2,610,553
Amounts due to related parties	11,902	12,015
Derivative financial instruments	291,531	153,292
Contract liabilities	757,323	681,863
Borrowings	1,403,699	120,000
Income tax payables	245,723	184,335
Financial liabilities at FVTPL	18,113	—
Rental Liabilities	109,038	—
	<u>5,601,828</u>	<u>3,762,058</u>
<b>Non-current Liabilities</b>		
Borrowings	815,000	15,000
Convertible bonds	1,883,489	—
Deferred tax liabilities	161,483	111,747
Deferred income	548,052	418,843
Derivative financial instruments	202,639	—
Financial liabilities at FVTPL	15,206	—
Rental liabilities	736,296	—
Other long-term liabilities	94,228	194,323
	<u>4,456,393</u>	<u>739,913</u>
<b>Capital and Reserves</b>		
Share capital	1,637,705	1,164,741
Reserves	15,581,456	16,523,280
	<u>17,219,161</u>	<u>17,688,021</u>
Equity attributable to owners of the Company	17,219,161	17,688,021
Non-controlling interests	93,025	477,210
	<u>17,312,185</u>	<u>18,165,231</u>